Literature DB >> 2881993

Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle.

M Tonini, C A Rizzi, E Perucca, F De Ponti, L D'Angelo, A Del Vecchio, A Crema.   

Abstract

Experiments were carried out in-vitro using segments of guinea-pig ileum, taenia caeci, ureter and detrusor. In the ileum, oxybutynin (30, 100 nM) competitively antagonized acetylcholine-induced contractions but did not alter those induced by histamine. Higher concentrations of oxybutynin (up to 10 microM) induced a non-competitive depression of responses to both agonists and caused a parallel shift to the right of the Ca2+-induced contractions in taenia caeci strips bathed in a Ca2+-free, high-K+ medium. In the ureter, oxybutynin (1-10 microM) impaired rhythmic muscular contractions in normal medium and after CaCl2 addition in Ca2+-free medium. Similarly to verapamil (10, 30 microM), oxybutynin (10, 30 microM) depressed both the cholinergic and non-adrenergic, non-cholinergic components of the electrically-induced contractions of detrusor strips. It is concluded that oxybutynin has anticholinergic properties and, at higher concentrations, exerts a direct spasmolytic activity possibly mediated by blockade of the transmembrane Ca2+ fluxes responsible for smooth muscle contraction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881993     DOI: 10.1111/j.2042-7158.1987.tb06953.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Extended-release oxybutynin.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-02       Impact factor: 3.923

3.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Transdermal oxybutynin: for overactive bladder.

Authors:  Lynne M Bang; Stephanie E Easthope; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.